新聞中心

Share to:

新聞中心

四大慢病用藥金額超700億!暢銷品種都在這!

    來源:醫藥經濟報(bao)

    目(mu)前,我國(guo)心(xin)腦血管(guan)(guan)疾病(bing)、癌癥(zheng)、慢性(xing)呼吸系統(tong)疾病(bing)、糖尿病(bing)這四類疾病(bing)為代表的慢性(xing)非傳(chuan)染性(xing)疾病(bing)導致的死(si)亡人(ren)(ren)數占(zhan)總(zong)死(si)亡人(ren)(ren)數的88%,導致的疾病(bing)負(fu)擔占(zhan)總(zong)疾病(bing)負(fu)擔的70%以(yi)上(shang)。7月15日(ri)發布的《國(guo)務(wu)院(yuan)關于實施健康中國(guo)行動的意見(jian)》(以(yi)下簡稱《意見(jian)》)提出,我國(guo)將針(zhen)對心(xin)腦血管(guan)(guan)疾病(bing)、癌癥、慢性(xing)呼吸系統疾病、糖尿病四類(lei)重(zhong)大慢性(xing)病開(kai)展防治行(xing)動。

    據國內樣本醫院數據統計(ji),2018年,抗腫瘤藥排名第3位(wei),銷(xiao)售額(e)為265億元(yuan),占11.6%;心血管系(xi)統用藥排名第4位(wei),銷(xiao)售額(e)為226億元(yuan),占10.0%;內分泌及代(dai)謝調節(jie)用藥(yao)(糖(tang)尿病(bing))排名(ming)第(di)7位,銷售額(e)為(wei)(wei)134億(yi)元(yuan),占(zhan)5.9%;呼吸系統藥(yao)物排名(ming)第(di)10位,銷售額(e)為(wei)(wei)81億(yi)元(yuan),占(zhan)3.5%。四類藥(yao)物銷售總額(e)為(wei)(wei)706億(yi)元(yuan),占(zhan)整體市場31.2%。 

     

    抗腫瘤藥

    2018年用藥金額為265億元,占11.7%

    《意見》倡導積極預(yu)防癌癥,推進早篩查、早診斷(duan)、早治療,降低癌癥發病率(lv)和死亡率(lv),提高患者生存質量(liang)。到2022年和2030年,總體(ti)癌癥5年生存率(lv)分別不低于(yu)43.3%和46.6%。

    從(cong)國內(nei)樣本醫院(yuan)數據看(kan),國內(nei)抗腫瘤(liu)藥市(shi)場規模從(cong)2012年的148億元增(zeng)長(chang)到2018年的265億元,6年整體(ti)市(shi)場增(zeng)長(chang)1.79倍。

    2018年國內(nei)樣本醫院排名前10位的腫瘤藥(yao)(yao)物(wu)中(zhong),抗(kang)代(dai)謝藥(yao)(yao)有(you):培(pei)美曲塞用(yong)藥(yao)(yao)金額(e)(e)為16.1億(yi)(yi)元(yuan)(yuan)(yuan)(yuan),較(jiao)(jiao)同(tong)(tong)期(qi)增(zeng)(zeng)(zeng)長(chang)13.3%;替(ti)吉奧(ao)用(yong)藥(yao)(yao)金額(e)(e)為12.9億(yi)(yi)元(yuan)(yuan)(yuan)(yuan),較(jiao)(jiao)同(tong)(tong)期(qi)增(zeng)(zeng)(zeng)長(chang)10.5%;卡(ka)培(pei)他濱用(yong)藥(yao)(yao)金額(e)(e)為9.9億(yi)(yi)元(yuan)(yuan)(yuan)(yuan),較(jiao)(jiao)同(tong)(tong)期(qi)增(zeng)(zeng)(zeng)長(chang)4.7%。植(zhi)物(wu)藥(yao)(yao)有(you):紫(zi)杉醇用(yong)藥(yao)(yao)金額(e)(e)為21.7億(yi)(yi)元(yuan)(yuan)(yuan)(yuan),較(jiao)(jiao)同(tong)(tong)期(qi)增(zeng)(zeng)(zeng)長(chang)6.4%;多西他賽用(yong)藥(yao)(yao)金額(e)(e)為13.8億(yi)(yi)元(yuan)(yuan)(yuan)(yuan),較(jiao)(jiao)同(tong)(tong)期(qi)增(zeng)(zeng)(zeng)長(chang)5.1%。單(dan)(dan)克隆抗(kang)體(ti)藥(yao)(yao)物(wu)有(you):曲妥珠(zhu)單(dan)(dan)抗(kang)用(yong)藥(yao)(yao)金額(e)(e)為13.1億(yi)(yi)元(yuan)(yuan)(yuan)(yuan),較(jiao)(jiao)同(tong)(tong)期(qi)增(zeng)(zeng)(zeng)長(chang)47.8%;利妥昔單(dan)(dan)抗(kang)用(yong)藥(yao)(yao)金額(e)(e)為12.2億(yi)(yi)元(yuan)(yuan)(yuan)(yuan),較(jiao)(jiao)同(tong)(tong)期(qi)增(zeng)(zeng)(zeng)長(chang)13.2%;貝(bei)伐(fa)珠(zhu)單(dan)(dan)抗(kang)用(yong)藥(yao)(yao)金額(e)(e)為10.0億(yi)(yi)元(yuan)(yuan)(yuan)(yuan),較(jiao)(jiao)同(tong)(tong)期(qi)增(zeng)(zeng)(zeng)長(chang)74.4%。鉑(bo)類化合(he)物(wu)有(you):奧(ao)沙利鉑(bo)用(yong)藥(yao)(yao)金額(e)(e)為10.0億(yi)(yi)元(yuan)(yuan)(yuan)(yuan),較(jiao)(jiao)同(tong)(tong)期(qi)增(zeng)(zeng)(zeng)長(chang)6.2%。靶向(xiang)小分子藥(yao)(yao)物(wu)有(you):伊馬替(ti)尼用(yong)藥(yao)(yao)金額(e)(e)為8.3億(yi)(yi)元(yuan)(yuan)(yuan)(yuan),較(jiao)(jiao)同(tong)(tong)期(qi)增(zeng)(zeng)(zeng)長(chang)18.2%。

    心(xin)腦血管藥(yao)

    2018年用藥(yao)金額為226億元,占10.0%

    《意(yi)見》指出,心(xin)腦血(xue)管疾病(bing)是我國居(ju)民第一位死亡原因,應(ying)引導居(ju)民學習掌握心(xin)肺復蘇等自救互(hu)救知識技能,對高危人群和患者(zhe)開(kai)展生活方式指導。到2022和2030年,心(xin)腦血(xue)管疾病(bing)死亡率分別下降到209.7/10萬及(ji)以下和190.7/10萬及(ji)以下。

    從國內樣本醫院數據(ju)來看,心血管系(xi)統用藥市場(chang)規(gui)模(mo)從2012年的177億元(yuan)增(zeng)長(chang)(chang)到(dao)2018年的226億元(yuan),6年整體(ti)市場(chang)增(zeng)長(chang)(chang)1.28倍。

    2018年國內樣本醫院用(yong)(yong)(yong)(yong)藥(yao)金(jin)(jin)額(e)排名前10位心血(xue)管系統用(yong)(yong)(yong)(yong)藥(yao)中,降血(xue)脂(zhi)藥(yao)有(you)(you)(you):阿托(tuo)伐他汀(ting)用(yong)(yong)(yong)(yong)藥(yao)金(jin)(jin)額(e)為(wei)(wei)(wei)24.1億(yi)(yi)元(yuan)(yuan)(yuan),較(jiao)同(tong)(tong)(tong)期(qi)(qi)增長(chang)(chang)9.16%;瑞舒伐他汀(ting)用(yong)(yong)(yong)(yong)藥(yao)金(jin)(jin)額(e)為(wei)(wei)(wei)8.3億(yi)(yi)元(yuan)(yuan)(yuan),較(jiao)同(tong)(tong)(tong)期(qi)(qi)增長(chang)(chang)7.37%。其它心血(xue)管系統用(yong)(yong)(yong)(yong)藥(yao)有(you)(you)(you):磷酸(suan)肌酸(suan)用(yong)(yong)(yong)(yong)藥(yao)金(jin)(jin)額(e)為(wei)(wei)(wei)11.9億(yi)(yi)元(yuan)(yuan)(yuan),較(jiao)同(tong)(tong)(tong)期(qi)(qi)下(xia)(xia)降30.44%;輔酶A/輔酶I用(yong)(yong)(yong)(yong)藥(yao)金(jin)(jin)額(e)為(wei)(wei)(wei)6.1億(yi)(yi)元(yuan)(yuan)(yuan),較(jiao)同(tong)(tong)(tong)期(qi)(qi)下(xia)(xia)降38.01%。鈣(gai)拮抗(kang)劑類有(you)(you)(you):氨(an)氯地平(ping)用(yong)(yong)(yong)(yong)藥(yao)金(jin)(jin)額(e)為(wei)(wei)(wei)7.8億(yi)(yi)元(yuan)(yuan)(yuan),較(jiao)同(tong)(tong)(tong)期(qi)(qi)增長(chang)(chang)3.1%;硝苯(ben)地平(ping)用(yong)(yong)(yong)(yong)藥(yao)金(jin)(jin)額(e)為(wei)(wei)(wei)6.7億(yi)(yi)元(yuan)(yuan)(yuan),較(jiao)同(tong)(tong)(tong)期(qi)(qi)增長(chang)(chang)7.62%。周圍(wei)血(xue)管擴張藥(yao)有(you)(you)(you):前列地爾用(yong)(yong)(yong)(yong)藥(yao)金(jin)(jin)額(e)為(wei)(wei)(wei)12.9億(yi)(yi)元(yuan)(yuan)(yuan),較(jiao)同(tong)(tong)(tong)期(qi)(qi)下(xia)(xia)降27.68%。beta-阻滯劑有(you)(you)(you):美托(tuo)洛(luo)爾用(yong)(yong)(yong)(yong)藥(yao)金(jin)(jin)額(e)為(wei)(wei)(wei)5.3億(yi)(yi)元(yuan)(yuan)(yuan),較(jiao)同(tong)(tong)(tong)期(qi)(qi)增長(chang)(chang)6.70%。血(xue)管緊張素Ⅱ受(shou)體拮抗(kang)劑有(you)(you)(you):纈(xie)沙坦用(yong)(yong)(yong)(yong)藥(yao)金(jin)(jin)額(e)為(wei)(wei)(wei)5.1億(yi)(yi)元(yuan)(yuan)(yuan),較(jiao)同(tong)(tong)(tong)期(qi)(qi)下(xia)(xia)降5.03%。

    內(nei)分(fen)泌及代謝(xie)調(diao)節用藥(糖尿病(bing))

    2018年用藥(yao)金(jin)額為134億元,占(zhan)5.9%

    《意見》指出,我國(guo)是糖(tang)尿(niao)(niao)病(bing)患病(bing)率(lv)增長最快(kuai)的國(guo)家之一,提(ti)示居民關注(zhu)血糖(tang)水平(ping),引(yin)導糖(tang)尿(niao)(niao)病(bing)前期(qi)人群科學降低(di)發(fa)(fa)病(bing)風險,指導糖(tang)尿(niao)(niao)病(bing)患者(zhe)加強(qiang)健康(kang)管(guan)理,延遲或預(yu)防糖(tang)尿(niao)(niao)病(bing)的發(fa)(fa)生(sheng)發(fa)(fa)展。到2022年和2030年,糖(tang)尿(niao)(niao)病(bing)患者(zhe)規范管(guan)理率(lv)分(fen)別達(da)到60%及以上和70%及以上。

    從國內樣本(ben)醫院數(shu)據來看,內分(fen)泌及代謝(xie)調節用藥(糖(tang)(tang)尿病(bing))市(shi)場規模從2012年的(de)(de)80.3億元增(zeng)(zeng)長到2018年的(de)(de)134億元,較同期增(zeng)(zeng)長5.9%,6年整體市(shi)場增(zeng)(zeng)長1.67倍。其中涉及糖(tang)(tang)尿病(bing)小類(lei)有:口服血(xue)糖(tang)(tang)調節藥、胰島素、糖(tang)(tang)尿病(bing)綜(zong)合征用藥、DPP-IV抑制劑、GLP-1類(lei)似(si)物。

    2018年國內樣(yang)本醫院(yuan)用(yong)(yong)(yong)(yong)(yong)藥(yao)(yao)(yao)金(jin)額(e)(e)(e)排名前10位(wei)的(de)糖(tang)尿病藥(yao)(yao)(yao)物(wu)中,口服血(xue)糖(tang)調節藥(yao)(yao)(yao)有:阿卡波(bo)糖(tang)用(yong)(yong)(yong)(yong)(yong)藥(yao)(yao)(yao)金(jin)額(e)(e)(e)為(wei)(wei)11.6億(yi)(yi)(yi)元(yuan)(yuan),較(jiao)同(tong)期增(zeng)(zeng)長(chang)(chang)6.2%;二甲雙胍用(yong)(yong)(yong)(yong)(yong)藥(yao)(yao)(yao)金(jin)額(e)(e)(e)為(wei)(wei)5.7億(yi)(yi)(yi)元(yuan)(yuan),較(jiao)同(tong)期增(zeng)(zeng)長(chang)(chang)10.6%;格(ge)列(lie)(lie)美脲(niao)用(yong)(yong)(yong)(yong)(yong)藥(yao)(yao)(yao)金(jin)額(e)(e)(e)為(wei)(wei)3.0億(yi)(yi)(yi)元(yuan)(yuan),較(jiao)同(tong)期下降(jiang)(jiang)1.4%;瑞格(ge)列(lie)(lie)奈用(yong)(yong)(yong)(yong)(yong)藥(yao)(yao)(yao)金(jin)額(e)(e)(e)為(wei)(wei)2.5億(yi)(yi)(yi)元(yuan)(yuan),較(jiao)同(tong)期下降(jiang)(jiang)6.3%;格(ge)列(lie)(lie)齊特用(yong)(yong)(yong)(yong)(yong)藥(yao)(yao)(yao)金(jin)額(e)(e)(e)為(wei)(wei)2.1億(yi)(yi)(yi)元(yuan)(yuan),較(jiao)同(tong)期增(zeng)(zeng)長(chang)(chang)2.8%。胰(yi)島(dao)(dao)素(su)有:甘精胰(yi)島(dao)(dao)素(su)用(yong)(yong)(yong)(yong)(yong)藥(yao)(yao)(yao)金(jin)額(e)(e)(e)為(wei)(wei)28.2億(yi)(yi)(yi)元(yuan)(yuan),較(jiao)同(tong)期增(zeng)(zeng)長(chang)(chang)6.4%;門冬胰(yi)島(dao)(dao)素(su)用(yong)(yong)(yong)(yong)(yong)藥(yao)(yao)(yao)金(jin)額(e)(e)(e)為(wei)(wei)7.1億(yi)(yi)(yi)元(yuan)(yuan),較(jiao)同(tong)期增(zeng)(zeng)長(chang)(chang)55.9%;賴脯胰(yi)島(dao)(dao)素(su)用(yong)(yong)(yong)(yong)(yong)藥(yao)(yao)(yao)金(jin)額(e)(e)(e)為(wei)(wei)2.4億(yi)(yi)(yi)元(yuan)(yuan),較(jiao)同(tong)期增(zeng)(zeng)長(chang)(chang)0.3%。糖(tang)尿病綜(zong)合(he)征用(yong)(yong)(yong)(yong)(yong)藥(yao)(yao)(yao)硫(liu)辛(xin)酸用(yong)(yong)(yong)(yong)(yong)藥(yao)(yao)(yao)金(jin)額(e)(e)(e)為(wei)(wei)3.9億(yi)(yi)(yi)元(yuan)(yuan),較(jiao)同(tong)期下降(jiang)(jiang)14.1%。DPP-IV抑制劑西(xi)格(ge)列(lie)(lie)汀(ting)用(yong)(yong)(yong)(yong)(yong)藥(yao)(yao)(yao)金(jin)額(e)(e)(e)為(wei)(wei)2.3億(yi)(yi)(yi)元(yuan)(yuan),較(jiao)同(tong)期增(zeng)(zeng)長(chang)(chang)99.5%。

    呼吸(xi)系統藥物

    2018年(nian)用(yong)藥(yao)金(jin)額(e)為80.6億元,占(zhan)3.5%

    《意見》指出,慢性(xing)(xing)呼吸系統疾病嚴重影響患者生活質量,應引(yin)導重點人(ren)群(qun)早期發(fa)(fa)現(xian)疾病,控制危險因素,預防疾病發(fa)(fa)生發(fa)(fa)展。到2022年和2030年,70歲(sui)及以下(xia)(xia)人(ren)群(qun)慢性(xing)(xing)呼吸系統疾病死(si)亡(wang)率下(xia)(xia)降(jiang)到9/10萬及以下(xia)(xia)和8.1/10萬及以下(xia)(xia)。

    從國(guo)內樣本醫院(yuan)數據來看,呼吸系(xi)統藥(yao)物市場(chang)(chang)規模從2012年(nian)(nian)的47.4億元增長(chang)到2018年(nian)(nian)的80.6億元,較同期增長(chang)3.1%,6年(nian)(nian)整體市場(chang)(chang)增長(chang)1.7倍。

    2018年國內(nei)樣(yang)本醫院用(yong)藥(yao)(yao)(yao)金額(e)(e)排名前(qian)10位的(de)呼(hu)吸系統藥(yao)(yao)(yao)物(wu)中(zhong),平喘(chuan)藥(yao)(yao)(yao)有:布地奈德用(yong)藥(yao)(yao)(yao)金額(e)(e)為(wei)12.5億(yi)元,較同(tong)期(qi)(qi)(qi)增(zeng)長(chang)(chang)10.8%;孟(meng)魯(lu)司特用(yong)藥(yao)(yao)(yao)金額(e)(e)為(wei)6.1億(yi)元,較同(tong)期(qi)(qi)(qi)增(zeng)長(chang)(chang)11.0%;布地奈德/福(fu)莫(mo)特羅用(yong)藥(yao)(yao)(yao)金額(e)(e)為(wei)4.1億(yi)元,較同(tong)期(qi)(qi)(qi)增(zeng)長(chang)(chang)10.2%;多索(suo)茶(cha)堿用(yong)藥(yao)(yao)(yao)金額(e)(e)為(wei)3.5億(yi)元,較同(tong)期(qi)(qi)(qi)增(zeng)長(chang)(chang)3.0%;沙美特羅/氟替(ti)卡松用(yong)藥(yao)(yao)(yao)金額(e)(e)為(wei)2.7億(yi)元,較同(tong)期(qi)(qi)(qi)增(zeng)長(chang)(chang)0.1%。祛痰(tan)藥(yao)(yao)(yao)有:氨(an)溴(xiu)索(suo)用(yong)藥(yao)(yao)(yao)金額(e)(e)為(wei)10.4億(yi)元,較同(tong)期(qi)(qi)(qi)下降16.2%;乙酰半胱(guang)氨(an)酸用(yong)藥(yao)(yao)(yao)金額(e)(e)為(wei)6.3億(yi)元,較同(tong)期(qi)(qi)(qi)增(zeng)長(chang)(chang)15.5%。COPD治療藥(yao)(yao)(yao)噻托溴(xiu)銨用(yong)藥(yao)(yao)(yao)金額(e)(e)為(wei)2.9億(yi)元,較同(tong)期(qi)(qi)(qi)增(zeng)長(chang)(chang)12.7%。止咳祛痰(tan)平喘(chuan)藥(yao)(yao)(yao)蘇黃止咳膠囊用(yong)藥金額為2.8億元,較同(tong)期(qi)增(zeng)長26.0%。清熱解毒(du)藥(yao)喜炎平注射液用藥金(jin)額為2.7億(yi)元(yuan),較同期下降43.6%。

    網(wang)站免責聲明:
    1.湖(hu)北(bei)海鴻醫(yi)藥有限(xian)(xian)公司(si)(si)對本網站上刊登之所(suo)有信(xin)息(xi)不聲明或保證其(qi)內容之正(zheng)確性(xing)或可靠性(xing);您于此接(jie)受并承認信(xin)賴(lai)任何信(xin)息(xi)所(suo)生之風險應自行承擔。湖(hu)北(bei)海鴻醫(yi)藥有限(xian)(xian)公司(si)(si),有權(quan)但無(wu)此義務,改善或更(geng)正(zheng)所(suo)刊登信(xin)息(xi)任何部分(fen)之錯(cuo)誤或疏失(shi)。
    2.凡本(ben)(ben)網站(zhan)注明"來源:XXX(非本(ben)(ben)網站(zhan))"的作品,均轉(zhuan)載(zai)自其(qi)它媒體(ti)(ti),轉(zhuan)載(zai)目的在于傳遞更多信息,并不(bu)代表本(ben)(ben)網站(zhan)贊同其(qi)觀點和對其(qi)真實性負責。本(ben)(ben)網轉(zhuan)載(zai)其(qi)他媒體(ti)(ti)之稿(gao)件,意在為公(gong)眾提(ti)供免費服務。如稿(gao)件版(ban)權(quan)單(dan)位(wei)或(huo)個人不(bu)想在本(ben)(ben)網站(zhan)發布(bu),可(ke)與本(ben)(ben)網站(zhan)聯系,本(ben)(ben)網站(zhan)視(shi)情況可(ke)立(li)即將其(qi)撤除。
    聯系電(dian)話:027-84877900  郵件:1015566216@qq.com